Bristol-Myers Squibb stock (US1078421011): $15.2B Hengrui drug partnership

Bristol-Myers Squibb revealed a landmark collaboration with Hengrui Pharma on May 12, 2026, potentially valued at up to $15.2 billion. The partnership spans 13 early-stage programs in oncology, hematology and immunology, with Bristol-Myers Squibb paying $600 million upfront and additional milestone payments. The companies will split global rights, with Hengrui leading early clinical development, according to NJBIZ as of 05/12/2026 and BioPharma Dive as of 05/12/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb focuses on discovering, developing and delivering innovative medicines for patients with serious diseases. The company concentrates on oncology, hematology, immunology, cardiovascular and neuroscience therapeutic areas. Its portfolio includes blockbuster drugs like Opdivo for cancer immunotherapy and Eliquis for anticoagulation, which drive significant revenue. Headquartered in New Jersey, Bristol-Myers Squibb maintains a global footprint with manufacturing and R&D sites worldwide, emphasizing partnerships to bolster its pipeline amid patent expirations.

Main revenue and product drivers for Bristol-Myers Squibb

Oncology remains the largest revenue contributor, with products like Opdivo and Yervoy generating billions annually. Immunology drugs such as Orencia and the recently approved Sotyktu for psoriasis also play key roles. Cardiovascular therapies, led by Eliquis in partnership with Pfizer, account for a substantial share. In 2025 full-year results published in early 2026, the company reported steady growth in these areas despite generic competition, per its investor relations filings.

Industry trends and competitive position

The biopharma sector faces pressures from patent cliffs and rising R&D costs, pushing companies toward strategic alliances, particularly with innovative biotech firms in China. Bristol-Myers Squibb's deal with Hengrui positions it to access novel modalities in oncology and immunology, areas of high unmet need. Competitors like Merck and Pfizer are similarly pursuing global partnerships to refresh pipelines. This collaboration enhances Bristol-Myers Squibb's competitive edge in next-generation therapies for US and international markets.

Why Bristol-Myers Squibb matters for US investors

As a NYSE-listed blue-chip stock, Bristol-Myers Squibb offers US investors exposure to the resilient US healthcare market, which represents over 40% of its revenue. Its strong dividend yield and focus on high-growth areas like immuno-oncology align with defensive growth strategies. The Hengrui partnership underscores its strategy to leverage global innovation for US-listed assets, providing diversified risk amid domestic drug pricing debates.

Conclusion

The Hengrui partnership marks a significant step for Bristol-Myers Squibb in bolstering its pipeline through international collaboration, with potential value up to $15.2 billion and closure expected in Q3 2026. This deal highlights ongoing efforts to address pipeline gaps via external innovation. Investors will monitor progress on the 13 programs and milestone achievements amid a competitive biopharma landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.